### [2016-10-7](/news/2016/10/7/index.md)

# Mylan pays US$465 million to settle its underpayment to U.S. government healthcare programs by misclassifying its epinephrine autoinjector emergency allergy treatment. 

Mylan NV (MYL.O) on Friday said it will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment, which has come under intense scrutiny after a series of drastic price increases.


### Source:

1. [Reuters](http://www.reuters.com/article/us-mylan-nl-epipen-idUSKCN1272DZ?il=0)
1. [Cover Image](http://s3.reutersmedia.net/resources/r/?m=02&d=20161007&t=2&i=1156600534&w=&fh=545px&fw=&ll=&pl=&sq=&r=LYNXNPEC961NO)

### Related:

1. [Israeli generics giant Teva Pharmaceutical offers $4 billion to acquire US rival Mylan. ](/news/2015/04/21/israeli-generics-giant-teva-pharmaceutical-offers-4-billion-to-acquire-us-rival-mylan.md) _Context: Mylan_
2. [Mylan, a manufacturer of generic drugs, announced that its board has no interest in much-discussed prospect of purchase by Teva Pharmaceuticals, one of the 15 largest pharmaceutical concerns in the world. ](/news/2015/04/17/mylan-a-manufacturer-of-generic-drugs-announced-that-its-board-has-no-interest-in-much-discussed-prospect-of-purchase-by-teva-pharmaceutic.md) _Context: Mylan_
